{"id":"W2737220576","doi":"10.1200/jco.2013.31.15_suppl.574","title":"Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Sunnybrook Health Science Centre; McMaster University; Grand River Hospital; Ottawa Hospital; BC Cancer Agency; Health Sciences Centre; Ontario Clinical Oncology Group; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; N-terminal telopeptide; Placebo; Bone remodeling; Gastroenterology; Vandetanib; Fulvestrant; Breast cancer; Oncology; Urology; Endocrinology; Cancer; Estrogen receptor; Pathology; Receptor; Osteocalcin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001229492,0.002032031,0.00348701,0.0004934911,0.0004764042,0.001126708,0.001275328,0.001793228,0.01332106],"category_scores_gemma":[0.001419589,0.0008547181,0.001312598,0.0004489798,0.001325265,0.000922886,0.0005043679,0.003034126,0.002022975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001049392,"about_ca_system_score_gemma":0.001277446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002895453,"about_ca_topic_score_gemma":0.007280267,"domain_scores_codex":[0.9996153,0.0001618971,0.00001916731,0.0000692783,0.00002686246,0.0001075368],"domain_scores_gemma":[0.9993861,0.0001124605,0.0001704184,0.00005390018,0.00004160644,0.0002356426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9855796,0.003335659,0.0002804408,0.0004159819,0.0004179465,0.00002149018,0.00003006885,0.0001618282,0.00181321,0.00008399044,0.00084155,0.00701816],"study_design_scores_gemma":[0.9745113,0.02364019,0.0009420008,0.0000150539,0.0001456704,0.00001292138,0.00001255334,0.000113182,0.0001014285,0.00006100068,0.0004388262,0.000005900546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9694744,0.007130408,0.0008152545,0.001478299,0.001168571,0.01156014,0.003395229,0.0003298192,0.004647941],"genre_scores_gemma":[0.9705704,0.003595639,0.00142727,0.001789812,0.0006133955,0.01081715,0.002580051,0.00003974689,0.008566498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01332106,"threshold_uncertainty_score":0.04456341,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04259018693465635,"score_gpt":0.416951622254952,"score_spread":0.3743614353202956,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}